Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestris, Nicola, Brunetti, Oronzo, Bittoni, Alessandro, Cataldo, Ivana, Corsi, Domenico, Crippa, Stefano, D’Onofrio, Mirko, Fiore, Michele, Giommoni, Elisa, Milella, Michele, Pezzilli, Raffaele, Vasile, Enrico, Reni, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352458/
https://www.ncbi.nlm.nih.gov/pubmed/32599886
http://dx.doi.org/10.3390/cancers12061681
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

Ejemplares similares